Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.
Yingzhao HuangBowen LiuJile ShiSen ZhaoKexin XuLiying SunNa ChenWen TianTerry Jianguo ZhangNan WuPublished in: Journal of personalized medicine (2022)
Clinical exome sequencing (CES) has shown great utility in the diagnosis of Mendelian disorders. CES can unravel secondary findings (SFs) unrelated to the primary diagnosis but with potential health implications. The American College of Medical Genetics and Genomics (ACMG) has published a guideline for reporting secondary findings and recently updated an ACMG SF v3.0 list comprising 73 genes. Several studies have been performed to explore the prevalence of SFs. However, the data were limited in the Chinese population. In this study, we evaluated the genetic data of 2987 individuals from the Deciphering Disorders Involving Scoliosis and COmorbidities (DISCO) study group in accordance with the ACMG SF v3.0 list. The detected variants were evaluated using the ACMG classification guidelines, HGMD, and ClinVar database. Totally, 157 (157/2987, 5.3%) individuals had reportable variants within genes associated with cancer, cardiovascular, metabolic, and miscellaneous phenotypes. We identified 63 known pathogenic (KP) variants in 72 individuals (72/2987, 2.4%) and 96 expected pathogenic (EP) variants in 105 individuals (3.5%). Forty-five individuals carried SFs in v3.0 newly added genes, which accounted for 1.5% of our cohort. Our findings could contribute to existing knowledge of secondary findings in different ethnicities and indicate the necessity for clinicians to update the SFs gene list.
Keyphrases
- copy number
- genome wide
- healthcare
- single cell
- primary care
- machine learning
- public health
- dna methylation
- electronic health record
- big data
- genome wide identification
- gene expression
- deep learning
- climate change
- risk assessment
- palliative care
- mental health
- adverse drug
- human health
- social media
- data analysis
- genome wide analysis